Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Nuffield Department of Primary Care Health Sciences at the University of Oxford and the Royal College of General Practitioners (RCGP) have joined forces with clinical system supplier EMIS Health to urgently recruit as many GP practices as possible for COVID-19 research.

Today, the Oxford RCGP’s Research and Surveillance Centre (RSC) has written to nearly 4,000 GP practices in England using EMIS Health systems asking them to contribute patient data to help them develop a deeper understanding of the COVID-19 pandemic in general practice.

The data – shared under strict governance guidelines – will enable researchers to understand the spread of COVID-19, including tracking when it peaks and helping to inform government strategy around measures such as social distancing and lockdown. Practices are also being asked to support public health surveillance by supplying samples from symptomatic patients and providing extra blood samples from asymptomatic patients having routine blood tests. Some practices are also being asked to take part in rapid clinical trials of selected medicines to reduce the duration and severity of the virus. The first trial will need up to 3,000 patients. As many practices as possible are needed to support the work.

Professor Richard Hobbs, Head of Department of Primary Care Health Sciences said, 'This has been an extraordinary collaborative effort to compress many months of work into a few days. We are finalising the first national COVID-19 trial outside of hospital, led by Professor Chris Butler; significantly extending the only national surveillance of COVID-19 outside of hospitals; and considering efficient COVID-19 information feedback to practices.'

Read the full story on the Department of Primary Care Health Sciences website

This story is also featured on the University of Oxford website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.